<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03660501</url>
  </required_header>
  <id_info>
    <org_study_id>WARD-COPD_v1.1</org_study_id>
    <nct_id>NCT03660501</nct_id>
  </id_info>
  <brief_title>Wireless Assessment of Respiratory and Circulatory Distress in Chronic Obstructive Pulmonary Disease - an Observational Study</brief_title>
  <acronym>WARD-COPD</acronym>
  <official_title>Continuous Vital Sign Monitoring During Admission for Acute Exacerbations of Chronic Obstructive Pulmonary Disease - an Observational Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Bispebjerg and Frederiksberg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Technical University of Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Herlev and Gentofte Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Bispebjerg and Frederiksberg</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      For patients admitted to the medical ward, it is often difficult to predict if their clinical
      condition will deteriorate, however subtle changes in vital signs are usually present 8 to 24
      hours before a life-threatening event such as respiratory failure leading to ICU admission,
      or unanticipated cardiac arrest. Such adverse trends in clinical observations can be missed,
      misinterpreted or not appreciated as urgent. New continuous and wearable 24/7 clinical vital
      parameter monitoring systems offer a unique possibility to identify clinical deterioration
      before patients condition progress beyond the point-of-no-return, where adverse events are
      inevitable. The WARD-COPD project aims to determine the correlation between cardiopulmonary
      micro events and clinical adverse events during the first four days after hospital admission
      with acute exacerbation of Chronic Obstructive Pulmonary Disease (AECOPD).
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 12, 2018</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Actual">December 21, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Any serious adverse events</measure>
    <time_frame>within 30 days after inclusion</time_frame>
    <description>E.g. cardiac arrest, ICU admission, acute myocardial infarction, stroke, sepsis, acute kidney injury or other serious adverse events (defined in Protocol Appendix A)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>within 6 months after inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Readmission</measure>
    <time_frame>within 6 months after inclusion</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">200</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Continuous monitoring system</intervention_name>
    <description>Patients recruited will be continuously monitored with Isansys Lifetouch patch, Isansys wireless blood pressure monitor, Nonin WristOx 3150, Empatica E4, and Radiometer TCM5 FLEX monitor.</description>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Troponin, Arterial Blood Gas
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        200 patients admitted to hospital with acute exacerbation of COPD will be included in the
        study upon arrival to the medical ward.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients admitted with AECOPD

          -  Recruitment and monitoring start is possible within 24 hours after admission

        Exclusion Criteria:

          -  Patient expected not to cooperate

          -  Patient allergic to plaster, plastic or silicone

          -  Active therapy withdrawn

          -  Patients with dementia or not able to give informed consent

          -  Patients with pacemaker or implantable cardioverter-defibrillator (ICD) unit

          -  Expected discharge within less than 24 hours from possible inclusion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian Meyhoff, MD, PHD</last_name>
    <role>Study Chair</role>
    <affiliation>Bispebjerg and Frederiksberg Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bispebjerg Hospital</name>
      <address>
        <city>Copenhagen</city>
        <zip>2400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gentofte Hospital</name>
      <address>
        <city>Hellerup</city>
        <zip>2900</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>September 4, 2018</study_first_submitted>
  <study_first_submitted_qc>September 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 6, 2018</study_first_posted>
  <last_update_submitted>March 9, 2020</last_update_submitted>
  <last_update_submitted_qc>March 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Bispebjerg and Frederiksberg</investigator_affiliation>
    <investigator_full_name>Mikkel Elvekjaer</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Continuous monitoring</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

